602 reports of this reaction
2.0% of all LIFITEGRAST reports
#10 most reported adverse reaction
HEADACHE is the #10 most commonly reported adverse reaction for LIFITEGRAST, manufactured by Bausch & Lomb Incorporated. There are 602 FDA adverse event reports linking LIFITEGRAST to HEADACHE. This represents approximately 2.0% of all 29,776 adverse event reports for this drug.
Patients taking LIFITEGRAST who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for LIFITEGRAST, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for LIFITEGRAST:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 602 FDA reports for LIFITEGRAST. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.0% of all adverse event reports for LIFITEGRAST, making it a notable side effect.
If you experience headache while taking LIFITEGRAST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.